Randox Health to sponsor the two feature contests at The Showcase
Randox Health to sponsor the two feature contests at The Showcase
Randox is pleased to announce that Randox Health will sponsor two £50,000 handicap chases at The Showcase on Saturday, October 22 – the Randox Health Handicap Steeple Chase (3.30pm) over two miles and the Randox Handicap Steeple Chase (1.50pm) over three miles and a furlong.
Earlier this year, Randox Health signed a five-year agreement to become title sponsors of the Randox Health Grand National at Aintree from 2017 and was also unveiled as the official healthcare partner of The Jockey Club, joining an esteemed and growing list of Group Partners. By embarking on this Group-wide partnership the Jockey Club is striving to raise Randox Health’s message of preventive health and wellbeing amongst its members, and to the wider racing audience of all Jockey Club Racecourses.
The Randox Health Handicap Steeple Chase and the Randox Handicap Steeple Chase are the richest races over the two days of The Showcase, which gets Cheltenham’s new season underway on Friday and Saturday, October 21 and 22.
Popular chaser Balthazar King captured the Randox Handicap Steeple Chase three years on the bounce (2011, 2012, 2013) and was runner-up to Pineau De Re in the 2014 Grand National.
The Randox Health Handicap Steeple Chase, run at two and a half miles up to and including 2014, has provided some valuable pointers to the BetVictor Gold Cup at The Open in November. Johns Spirit captured both races in 2013, as did Shooting Light (2001) and The Outback Way (1999).
Dr. Peter FitzGerald, Founder and Managing Director of Randox Health, is looking forward to The Showcase which marks the beginning of the roll out of Randox Health branding across Jockey Club courses;
“We are thrilled to be able to bring the name of Randox Health to the participants and viewers of the Randox Handicap Steeple Chase and the Randox Health Handicap Steeple Chase. The races mark the beginning of our partnership with the Jockey Club, whose courses are the perfect platform to highlight the benefits of our Randox Health Preventive Health Programmes to the public, and also to bring the other diagnostic capabilities of our healthcare company, including Equine Health and Food Testing, amongst others, to the attention of equestrian enthusiasts. Our health is our most valuable commodity and so we want to keep the horse racing fraternity healthy so they are able to enjoy such fantastic events as The Showcase.”
Carey Buckler, Regional Head of Partnerships, South West Region, Jockey Club Racecourses, said: “I am delighted that Randox Health are to sponsor at Cheltenham during The Showcase.
“Their involvement with The Jockey Club is really exciting and it is great that we are able to work with them across the group ahead of next year’s Randox Health Grand National.”
For further information please contact our Randox Comms Team on 028 9445 1016 or email amy.mcilwaine@randox.com
Randox and Chan Zuckerberg Initiative share common goal
You may have read in the news this week that the Chan Zuckerberg Initiative co-founded by Mark Zuckerberg has pledged to invest $3 billion over the next decade to help further and advance medical research. Investments will go towards a research facility, named the Biohub, which will focus on developing new tools to research, understand and treat diseases, and of particular interest to us here at Randox, on creating a chip to diagnose disease.
Here at Randox we fully support this drive to further research that is devoted to revolutionising healthcare. We commit up to 16% of turnover to research and development each year and currently over 20% of the world’s major laboratories are using Randox products.
In particular, we invested £220 million into the development of our Biochip Array Technology (BAT). The Randox biochip has revolutionised the diagnostics industry by facilitating the detection of a wide range of markers of disease from a single undivided sample. This not only enhances patient diagnosis but reduces the amount of time spent on individual tests and associated laboratory costs.
Our expertise, highly specialised scientists and world-class ISO accredited manufacturing facilities enables early, accurate, informed clinical decisions in the areas of veterinary testing, molecular research and diagnostics, drug development, food safety and forensic and clinical toxicology.
Our Randox Health clinics use our Biochip to allow people to avail of the complete portfolio of Randox routine and novel tests to empower their health decisions. This new and exciting service provides personalised and preventive health profiling for each individual.
Speaking about the biochip Dr. Peter FitzGerald, Founder and Managing Director of Randox said,
“Many years of development and the expertise of our highly qualified scientists have gone into the creation of Randox Biochip Array Technology. This scientific development will facilitate the simultaneous quantitative or qualitative detection of a wide range of analytes from a single undivided sample. This approach both proteomic and genomic enables an enhanced patient diagnosis, optimum efficiency and consolidation of cost. Our arrays are suitable for use in a wide range of settings including clinical and research laboratories, biopharmaceutical organisations, forensic and clinical toxicology, hospital laboratories, food testing and veterinary laboratories.”
We are delighted that Chan Zuckerberg’s interest in this area brings to the forefront the importance of improving healthcare through innovative diagnostics. It is clear that Randox and the Chan Zuckerberg Initiative share a common goal to revolutionise healthcare worldwide and we believe that the Randox Biochip can play an important role in realising this vision.
For further information please contact our Randox Comms Team on 028 9445 1016 or email amy.mcilwaine@randox.com
Grand National sponsor Randox hosts Polo event in Bushmills, Northern Ireland
New Grand National sponsor, Randox hosted a unique event in Bushmills this weekend – an International Polo tournament with teams taking part from Northern Ireland, the Republic of Ireland, Scotland, and South Africa.
Guests from around the world who made the journey to Northern Ireland for the Polo event were given a warm welcome – they were treated to an intimate performance from world renowned concert pianist Barry Douglas on the evening of Friday 16th September, in the recently acquired Dundarave Estate.
The Randox NI Polo was the first of its kind and over 500 guests made their way to the North Coast town to attend the inaugural event. The day kicked off with the Police Service Northern Ireland pipe band who entertained the crowds before the tournament began. Guests included Pamela Ballantine and the Lord-Lieutenant of County Antrim, Mrs. Joan Christie OBE who delivered the match ball of the opening game.
It was a victory for Scotland during the first nail-biting game of the tournament, as they went head to head with the team from Northern Ireland. But it was South Africa who emerged the winners of the 2016 tournament, after beating the team from the Republic of Ireland and scoring more goals than any other team. The weekend’s events ended with a Gala Ball and dinner, followed by a breath-taking firework display which was also enjoyed by members of the Bushmills community.
Randox Founder and Managing Director, Dr. Peter FitzGerald, a keen horseman and horse sports enthusiast, said he is looking forward to the highly anticipated Polo event;
“We’ve been engaged on the Point-to-Point scene in Northern Ireland for many years, close to our Randox headquarters in County Antrim, but up until now have never had the opportunity to also host a Polo tournament in Northern Ireland. We’re delighted to be able to now hold the event in the beautiful scenery of the North Coast and to bring the Randox Health message to our Polo guests. By taking care of your wellbeing you can ensure that you enjoy days out in Northern Ireland – such as the Randox Polo event – to the fullest.”
Earlier this year, it was announced that Randox Health will sponsor the Grand National, in a five year deal which starts in 2017.
At the time of the sponsorship announcement earlier this year, FitzGerald commented;
“We see this partnership as a natural fit, as both organisations invest heavily in the future and we aim to use our partnership to promote a positive lifestyle and to bring enjoyment to millions of people. We care about people’s health and this is the people’s race.”
As the company expands and develops – more than 370 million people across 145 countries now receive medical diagnosis via Randox products – it seems fitting that Randox would move from the local horse sports scene to the world’s greatest race.
But the global healthcare company is remaining true to its roots, continuing to host the Point-to-Point events that have been synonymous with the company for so long. And by bringing the Polo event to Bushmills, and opening its doors to the public, Randox is saying ‘we haven’t forgotten where we come from.’
Randox unveils Future of Diagnostics Technology at Annual Global Distributorsā Conference
The future of diagnostic healthcare has been unveiled at the Randox Science Park in Antrim, as the company’s annual global distributors’ conference gets underway. Delegates from more than 90 countries are taking part in the world-leading healthcare firm’s three-day event at the Hilton Hotel in Templepatrick.
As well as discussions about developments in reagents and quality control products, participants enjoyed demonstrations of Randox’s patented Biochip Array Technology and its extensive range of analysers from the RX Series.
Melansha Fernando from Alpha and Omega Diagnostics in Sri Lanka said,
“Randox has released so many new products recently that laboratories in my country are increasingly interested in what it can offer. As a result I felt it important to come here to learn more about the new technologies. The truly global nature of the company has been impressed upon me after meeting colleagues from so many different countries – I’m delighted to have been able to take part.”
Speaking at the conference, Dr. Peter Fitzgerald said,
“All exporters are aware of the considerable challenges we must overcome in order to do business in the global market but year on year our teams across the world have helped to drive our success. One of the biggest challenges Randox faces is the one we put to ourselves, to deliver truly transformative technologies and improve health worldwide. We recently celebrated our £1 billionth sale and we now look to build on that achievement and accelerate our rate of growth. All of our profits go straight to either R&D, or the development of our infrastructure, so strong growth is key to our goal of revolutionising diagnostics and saving lives across the world.”
Susan Hammond, Global Reagents Sales Manager said,
“It is a pleasure to see the diversity of our distributors gathered together in one room, and recognize how far we have come as an international company. We dedicated Thursday to focusing on building relationships with our worldwide distributors to ensure that they attain the best product knowledge available. Over 100,000 end users employ Randox products and every second of every day 80 Randox tests are used across the world, and it is vital our distributors are kept up to date with every new development.”
For more information on the Distributors’ Conference contact Amy in our PR Team by calling 028 9445 1016 or email amy.mcilwaine@randox.com
Randox hosts Polo Weekend 2016 in Scotland
Piano, polo and cardiac risk profiles were part of the mix enjoyed by more than a hundred guests from around the world at the annual Randox Laboratories’ weekend in Scotland.
World-renowned concert pianist Barry Douglas launched the event at Gleneagles Hotel with an intimate recital of his new music, as well as performing O’Carolan’s “Farewell to Music” and Tchaikovsky’s “Autumn Song.” The evening concluded with dinner and a talk from Manufacturing Manager David Martin who presented Randox’s innovative plans for the future which included our new state of the art Science Park.
A range of impressive seminars were held on Saturday morning, many of which were live-streamed for the first time on our social media channels to international followers. Guests were shown ground-breaking studies completed using Randox products, with the potential to truly transform the way healthcare is delivered. Highlights included a talk by Professor Ray Sherwood from Kings College London who studied “Cytokines for Diagnosis of POEMS syndrome and Castleman Disease” and research by Dr Ibrahim Mansoor from the International Medical Centre in Jeddah on “Extended Lipid Profile, Roles of sLDL”.
The polo match ball was hand delivered to Dr Peter FitzGerald by the Red Devils Parachute Regiment who impressed the crowds by jumping from thousands of feet up in the air to land squarely on the field at Errol Park. Some of the world’s best players took part including Sébastien Pailloncy (3-goals) who wore the England jersey. After three games, England were crowned the 2016 winners, South Africa followed closely behind as the runner up while Scotland came in at third place.
As well as the action on the polo field, guests enjoyed browsing a selection of stalls assembled by the Prince’s Trust (Randox official corporate charity) which included businesses such as “Maddy Burrows Illustrations,” “My Fantasy Bouquet” and “The Family Tree”.
The weekend’s events concluded that evening with the Highland Ball and dinner, followed by a breath-taking firework display – which was also enjoyed by members of the Errol community!
Plans are already underway for our next Polo Weekend – held this weekend for the first time at Dundarave House in Bushmills, Northern Ireland.
Randox welcomes record number of people to its student placement and graduate programme
71 people including scientists, engineers and IT specialists, from across the UK and Europe are taking the first steps in their Randox careers this week, as the company celebrates a record intake to its student placements and graduate programmes.
Now in its 26th year of providing student placements and 6th year for graduate programmes, Randox is recognised internationally for providing world-class opportunities for students and graduates – one of the core reasons that the global diagnostics company was established in 1982. Thirty years on, its founder Dr Peter FitzGerald remains as committed as ever to championing new talent and driving innovation.
Nadine McKerrow, who graduated this summer with a 2.1 in Biomedical Science from Ulster University, said,
“It’s always been my ambition to work for Randox because of the value it puts into R&D which is my speciality. Not only does it invest 16% of turnover into it – which is something very few companies do, but it’s also building the Randox Science Park which will house pioneering R&D labs. The research we do is going to make an incredible difference to saving lives and improving health, and I’m very proud to be part of the team.”
One of a number of people who have moved to Northern Ireland to take up a placement post is Ross Moir, a Chemistry student from the University of Edinburgh. He said,
“When I go into the lab, I am working beside people who came up with the test that detects Alzheimer’s – it’s incredibly inspirational. I’m not standing on the side-lines either – I’m getting right into the nitty-gritty of the work here. On-the-job experience with a company that is right now developing more new tests than any other diagnostics company in the world is an amazing opportunity.”
Randox founder Dr Peter FitzGerald said,
“I am pleased to welcome these ambitious and bright young people from across the UK and Europe to join the Randox team; they are key to continuing our success. It is no exaggeration to say that during the course of their careers many of them, through their innovative work in diagnostics within the labs at Randox, will save lives. The importance of supporting STEM students has never been so important, a fact recognised by business and political leaders across the world, and here at Randox we are delighted to be playing a significant part in that.”
University students across a range of disciplines take part in a 50-week placement with Randox. They gain invaluable experience in fields ranging from Business and Marketing to Biological and Life Sciences, Graphic Design to Mathematics and Physics, and Engineering to Computer Technology. At the end of their placements, subject to attaining a 2.1 degree or above, students are offered a full-time position in their chosen field.
Graduates enter a two-year programme, which is divided into a series of six-month placements, designed to provide a valuable insight into a variety of roles and departments. Many of the successful graduates who join Randox in full-time positions after this have progressed to attain senior positions within the Company.
Randox Reagents: Solving the Problem of Heart Attack Misdiagnosis
A report has today revealed that almost a third of patients in England and Wales are being given a misdiagnosis following a heart attack, following a study of 243 NHS hospitals, conducted by researchers at Leeds University.
Timely evaluation of patients with chest pain and subsequently suspected heart attack is a major challenge for hospitals around the world, with chest pain typically representing around 5% of all visits to the Emergency Department (ED) and 25% of ED admissions. One of the biggest challenges facing emergency doctors now is how to prioritise people presenting with chest pain – to primarily deal with those suffering from a heart attack, and to be able to move those who are not, to a different ward, to alleviate the pressures of the overrun A&E departments.
Responding to the escalating misdiagnosis crisis in emergency hospitals across the globe, scientists at Randox Laboratories in the UK have developed a test which could help clinicians rule out heart attacks in patients immediately upon arrival at hospital; allowing clinicians to accurately prioritise those who have truly suffered heart attacks.
This Randox test, for Heart-type fatty acid-binding protein (H-FABP), is a highly sensitive biomarker for use in the earlier diagnosis of patients with suspected Acute Myocardial Infarction (AMI), enabling faster “rule-in” and “rule-out”. H-FABP is detectable as early as 30 minutes after chest pain onset, significantly earlier than traditionally used biomarkers such as Troponin or CK-MB , which typically require 6-12 hours to reach detectable concentrations.
Put simply, given that H-FABP is released earlier than traditional biomarkers used in diagnosing a heart attack, an earlier diagnosis is achievable.
A succession of recent international clinical trials have demonstrated that by combining H-FABP, via this new laboratory assay, with the existing tests already used in hospitals for for Troponin I or Troponin T, the sensitivity and negative predictive value for ruling out AMIs is significantly improved.
Growing evidence indicates that even when one of the newer generation of “highly sensitive” Troponin assays is used, utilising the combination of Troponin and H-FABP is superior to Troponin alone.
The value of H-FABP is not just in positive diagnosis – but doctors are beginning to see it as a means of ‘ruling out heart attack’ when a patient presents at A&E with chest pain.
Please do get in touch if you would like to find out more about our H-FABP test, and how this can go a long way in solving the heart attack misdiagnosis crisis, by emailing reagents@randox.com
We Are Randox | Randox Rugby Team Promote Healthy Work-Life Balance at Randox
As a global healthcare diagnostics company, we know a thing or two about health. And we know that taking time out from our busy lives to relax and unwind is important to stay healthy. Whether that’s taking your dog for a walk, meeting up with friends, getting lost in a good book, or playing your favourite sport.
Playing a competitive sport brings a wealth of benefits – it’s the perfect way to socialise and look after your health at the same time! Not only is it good for your physical health, but can go a long way in maintaining your mental wellbeing too.
There is great value in exercise and fresh air. However, it’s an unfortunate fact of life that most 9-5ers just don’t have the opportunity to indulge in this pleasure very often.
Randox, being a company serious about health and wellbeing, like to know we’re giving our employees the best opportunities to be as healthy as they can, and live their lives as fulfilled as possible.
Amongst many sports in which Randox encourages employees to take part, we encourage our employees to regularly take the time to engage in some friendly competition of 5-a-side rugby against each other. The County Antrim countryside, in which our Randox headquarters are located, is the perfect setting for an informal game of rugby – our rugby players can let off some steam and take in the scenery at the same time!
The team was banded together by Randox Founder and Managing Director, Dr. Peter FitzGerald, who occasionally joins in on the games himself! Dr. FitzGerald is a strong advocate of teamwork and camaraderie in the workplace.
Jonathan Acheson, Randox Health Sales Executive, who plays for our Randox Rugby Team, commented;
“At Randox we work hard but we play hard too! Our work can often be very fast-paced and Randox is expanding phenomenally – for example we’re all working towards our 5 year sponsorship of the Randox Health Grand National, beginning in 2017, which is keeping us all very busy. So it’s important that we take time to unwind and recharge our batteries. We’re lucky that we’re able to take advantage of being in such a lovely area of Northern Ireland – right beside Lough Neagh – and so we can get outside after work and have a good run-about!”
Follow Randox Careers on Facebook, Twitter and Instagram to stay up-to-date with the hashtag #WeAreRandox
Randox Biochip Blood Test detects Alzheimer’s Disease risk in 3 hours
Randox are delighted to announce that at this week’s American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Lab Expo, in Philadelphia, we have been presented with a NACB / AACC Distinguished Abstract Award for a new Randox Biochip Blood Test to identify Alzheimer’s Disease risk.
Or more specifically, an award for our “Development of a New Biochip Array for ApoE4 Classification from Plasma Samples using Immunoassay Based Methods!”
Out of 1024 posters presented at the diagnostics conference, which is the largest of its kind globally, the poster for our new ApoE4 test, presented by our R&D Scientist Dr. Emma Harte, was one of only 29 to receive this prestigious award.
Emma is one of a team of Randox scientists at our Teoranta site in Dungloe, Co. Donegal, Ireland who carried out this pioneering Alzheimer’s research.
The ApoE4 poster demonstrated the work involved in the development of our ApoE4 blood test, performed on our patented Randox Biochip Array Technology. This blood test is an affordable method of identifying patients at risk of developing Alzheimer’s Disease, and provides a faster alternative to standard testing which analyses a patient’s DNA. Standard molecular testing can be both time-consuming and expensive.
The Randox ApoE4 Biochip Array can conduct multiple diagnostic tests on a single blood sample, which has both cost and time-saving benefits, in addition to a rapid diagnosis for the patient.
The Randox Biochip analyses the Apolipoprotein E (ApoE), a gene which is recognised as one of the most significant genetic risk factors for dementia and other neurodegenerative diseases.
There are three versions of the ApoE gene: E2, E3 and E4. The E4 version increases a person’s risk of developing late-onset Alzheimer’s disease, and it may also be associated with an earlier onset of memory loss.
Each parent passes on one ApoE gene to their child. Around 25% of the population inherit one copy of the ApoE4 gene. Inheriting two copies of the E4 variant increases a person’s disease risk by 10 times or more.
Our research into the identification of this gene was conducted in conjunction with our colleagues at the Medical University of Vienna, and verified the accuracy of the Randox Biochip Blood Test by analysing 384 samples and comparing the results to that of a standard molecular diagnostic test. Both tests provided the same accurate results, however the Biochip test results were available in a significantly faster 3 hours.
In combination with information on medical and family history, medication, and lifestyle, an individual’s ApoE4 status, as obtained from the Randox Biochip test, can go a long way in advising personalised medicine for the patient.
“This type of testing is important in our quest to understand and diagnose Alzheimer’s and empower patients to understand risks, consider medication, and even make early lifestyle changes,” said Emma, our R&D Scientist.
“Pairing this test with medical and family history for risk of Alzheimer’s disease has the real potential to advance personalised medicine. This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer’s.”
Dr. Emma Harte PhD, one of our Randox R&D Scientists! Emma presented our ApoE4 poster at this week’s AACC Annual Meeting and Clinical Lab Expo, in Philadelphia.
New Randox project committed to helping bladder cancer patients
Scientists at global healthcare company Randox, recently unveiled as the sponsors for The Grand National 2017 under the banner of Randox Health, today announced the company has been awarded an Innovate UK research award, for their pioneering work in the development of a diagnostic test for the detection of bladder cancer in haematuria patients.
The urine-based test is being developed in collaboration with The Belfast Trust and Queen’s University Belfast, and has been described by the project’s Lead Scientist at Randox, Dr Mark Ruddock, as the “holy grail” of diagnostic tests to stratify patients with haemeaturia (blood in the urine), who are at high risk of bladder cancer;
“Currently, all haematuria patients are ‘red-flagged’ as candidates for an invasive procedure called a cystoscopy (a camera inserted into the bladder), which is both embarrassing and uncomfortable for the patient. In comparison, the revolutionary Randox test is based on a simple urine sample so is non-invasive and much more comfortable for the patient.”
Considering less than 20% of patients with visible haematuria, and less than 5% with invisible haematuria are found to have bladder cancer, Dr Ruddock highlighted the urgent need for a test that can inform decisions for patients who present with haematuria;
“In the UK, over £33.5 million is spent each year managing patients with haematuria who are subsequently found not to have bladder cancer. As such, haematuria is a significant healthcare burden, which is only set to increase because of our aging population. Use of this new test will allow urology teams the opportunity to reduce the number of unnecessary cystoscopies carried out on patients identified as ‘low risk’, and stratify patients identified as ‘high risk’. This will result in significant healthcare savings, and an improvement in the waiting times for haematuria patients who do require diagnostic services ie. those patients deemed ‘high-risk’.”
Randox was successful in winning funding for phase one of the project, which has enabled an economic study to be carried out by The National Institute for Health Research Diagnostic Evidence Co-Operative Leeds who will investigate the economic benefits of the new diagnostic test for The National Health Service, and its role in the current patient care pathway. On successful completion of phase one, Randox will be eligible to apply for phase two funding.
Professor Peter Selby, Professor of Cancer Medicine at the University of Leeds, and Director of the NIHR Diagnostic Evidence Cooperative Leeds, said:
“Bladder cancer is a very important disease which can be life threatening but also in many patients it can generate great anxiety, frequent hospital visits and many investigations. The new approach being developed by Randox has the potential to save lives and improve the quality of lives of many people at risk of bladder cancer.”
“Diagnostic Classifier for risk stratification of haematuria patients” was selected by Innovate UK in the “Stratified Medicine: connecting the UK infrastructure” competition.
